560 Critical Care December 2005 Vol 9 No 6 Grounds and Bolan Following the publication of the above article [1], we noticed that the Competing interests section was incorrect and should read as follows: RMG has worked as a consultant for Novo Nordisk and lectured on behalf of Novo Nordisk about NovoSeven. References 1. Grounds RM, Bolan C: Clinical experiences and current evi- dence for therapeutic recombinant factor VIIa treatment in nontrauma settings. Crit Care 2005, 9(Suppl 5):S29-S36. Correction Correction: Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings R Michael Grounds 1 and Charles Bolan 2 1 Adult Intensive Care Unit, St George's Hospital, London, UK 2 COL (retired) US Army Medical Corps, Deputy Chief, Blood Services Section, Department of Transfusion Medicine, Clinical Centre, National Institutes of Health, Bethesda, Maryland, USA Corresponding author: R Michael Grounds, m.grounds@blueyonder.co.uk Published online: 4 November 2005 Critical Care 2005, 9:560 (DOI 10.1186/cc3926) This article is online at http://ccforum.com/9/6/560 © 2005 BioMed Central Ltd . in nontrauma settings. Crit Care 2005, 9(Suppl 5):S29-S36. Correction Correction: Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings R Michael. Nordisk and lectured on behalf of Novo Nordisk about NovoSeven. References 1. Grounds RM, Bolan C: Clinical experiences and current evi- dence for therapeutic recombinant factor VIIa treatment in nontrauma. Grounds and Bolan Following the publication of the above article [1], we noticed that the Competing interests section was incorrect and should read as follows: RMG has worked as a consultant for